| Literature DB >> 34550326 |
Raquel F Videira1,2,3, Anne Marie C Koop4, Lara Ottaviani1,2, Ella M Poels1, Jordy M M Kocken1,2, Cristobal Dos Remedios5, Pedro Mendes-Ferreira3, Kees W Van De Kolk6,7, Gideon J Du Marchie Sarvaas4, André Lourenço3, Aida Llucià-Valldeperas8, Dian aS Nascimento9,10,11, Leon J De Windt1,2, Frances S De Man8, Inês Falcão-Pires3, Rolf M F Berger4, Paula A da Costa Martins1,2,3.
Abstract
AIMS: Research on the pathophysiology of right ventricular (RV) failure has, in spite of the associated high mortality and morbidity, lagged behind compared to the left ventricle (LV). Previous work from our lab revealed that the embryonic basic helix-loop-helix transcription factor heart and neural crest derivatives expressed-2 (Hand2) is re-expressed in the adult heart and activates a 'foetal gene programme' contributing to pathological cardiac remodelling under conditions of LV pressure overload. As such, ablation of cardiac expression of Hand2 conferred protection to cardiac stress and abrogated the maladaptive effects that were observed upon increased expression levels. In this study, we aimed to understand the contribution of Hand2 to RV remodelling in response to pressure overload induced by pulmonary artery banding (PAB). METHODS ANDEntities:
Keywords: Hand2; Heart failure; Right ventricle remodelling; Transcriptional regulation
Mesh:
Substances:
Year: 2022 PMID: 34550326 PMCID: PMC9491876 DOI: 10.1093/cvr/cvab299
Source DB: PubMed Journal: Cardiovasc Res ISSN: 0008-6363 Impact factor: 13.081
MRI assessment of right ventricle function parameters of Hand2F/F and MCM-Hand2F/F mice at 2 and 6 weeks of sham or PAB
| Hand2F/F | MCM- Hand2F/F | |||||||
|---|---|---|---|---|---|---|---|---|
| Sham | PAB | Sham | PAB | |||||
| 2 weeks | 6 weeks | 2 weeks | 6 weeks | 2 weeks | 6 weeks | 2 weeks | 6 weeks | |
| Stroke volume (µL) | 27.0 ± 3.2 | 21.1 ± 1.1 | 24.0 ± 2.1 | 24.9 ± 2.4 | 26.9 ± 2.3 | 23.8 ± 4.0 | 25.9 ± 1.8 | 23.1 ± 2.8 |
| Cardiac output (mL/min) | 14.1 ± 1.3 | 11.1 ± 1.3 | 10.0 ± 0.9[ | 10.4 ± 0.8[ | 12.9 ± 0.8 | 13.3 ± 1.3 | 11.9 ± 0.6 | 10.6 ± 1.0[ |
| ED volume (µL) | 71.2 ± 8.9 | 72.0 ± 6.8 | 84.1 ± 12.5 | 91.7 ± 13.5 | 66.5 ± 3.1 | 68.8 ± 6.1 | 116.9 ± 7.4*# | 117.8 ± 10.7*# |
| ES volume (µL) | 44.1 ± 5.8 | 50.9 ± 6.1 | 60.1 ± 14.4 | 66.7 ± 12.7[ | 39.5 ± 3.9 | 45.1 ± 2.5 | 91.0 ± 6.2*# | 94.7 ± 10.2*# |
| ED mass (mg) | 22.6 ± 1.7 | 22.3 ± 4.7 | 30.1 ± 3.2[ | 32.9 ± 3.8[ | 22.2 ± 2.8 | 23.2 ± 2.0 | 33.9 ± 2.6[ | 37.8 ± 2.0[ |
| ES mass (mg) | 20.4 ± 2.1 | 24.3 ± 2.2 | 29.9 ± 4.9 | 36.3 ± 4.7[ | 19.9 ± 2.4 | 21.6 ± 1.4 | 34.4 ± 1.2[ | 37.6 ± 3.1[ |
| EF (%) | 38.1 ± 1.9 | 38.2 ± 3.8 | 28.6 ± 2.0 | 26.1 ± 2.4[ | 40.9 ± 3.0 | 34.8 ± 2.3 | 22.3 ± 1.3*# | 19.4 ± 2.1*# |
Data are expressed as means ± SEM. ED, end-diastole; ES, end-systole; RV, right ventricle; EF, ejection fraction.
P < 0.05 vs. sham group.
P < 0.05 vs. experimental group. n.s.=5–10 animals per group.
Morphometric characteristics of Hand2F/F and MCM-Hand2F/F mice subjected to 6 weeks of sham or PAB
| Hand2F/F | MCM- Hand2F/F | |||
|---|---|---|---|---|
| Sham | PAB | Sham | PAB | |
|
| 5 | 6 | 6 | 10 |
| HW/BW (mg/g) | 5.6 ± 0.5 | 7.3 ± 0.7[ | 5.9 ± 0.7 | 7.9 ± 0.3[ |
| HW/TL (mg/mm) | 7.9 ± 0.5 | 9.2 ± 0.4 | 7.9 ± 0.6 | 10.0 ± 0.4[ |
| RVW (mg) | 29.2 ± 2.1 | 39.3 ± 1.1[ | 26.5 ± 3.1 | 44.4 ± 3.9[ |
| IVS+LV (mg) | 127.1 ± 7.1 | 151.8 ± 9.0[ | 138.3 ± 5.2 | 150.2 ± 10.3[ |
| Fulton index | 0.18 ± 0.02 | 0.25 ± 0.01[ | 0.19 ± 0.03 | 0.30 ± 0.02*# |
Data are expressed as means ± SEM. HW, heart weight; BW, body weight; TL, tibia length; RVW, right ventricle weight; IVS, intraventricular septum; LV, left ventricle.
P < 0.05 vs. sham group.
P < 0.05 vs. experimental group. n.s.=5–10 animals per group.
MRI assessment of LV function parameters of Hand2F/F and MCM-Hand2F/F mice at 2 and 6 weeks after PAB
| Hand2F/F | MCM- Hand2F/F | |||||||
|---|---|---|---|---|---|---|---|---|
| Sham | PAB | Sham | PAB | |||||
| 2 weeks | 6 weeks | 2 weeks | 6 weeks | 2 weeks | 6 weeks | 2 weeks | 6 weeks | |
| Stroke volume (µL) | 35.2 ± 0.9 | 32.3 ± 2.0 | 27.3 ± 3.9 | 23.3 ± 1.3[ | 38.6 ± 2.7 | 35.6 ± 2.4 | 21.7 ± 1.8[ | 22.1 ± 1.4[ |
| Cardiac output (mL/min) | 18.4 ± 0.4 | 16.9 ± 1.8 | 11.4 ± 1.7[ | 9.8 ± 0.5[ | 18.6 ± 0.8 | 17.1 ± 1.2 | 9.9 ± 0.7[ | 10.2 ± 0.6[ |
| ED volume (µL) | 92.7 ± 2.8 | 91.5 ± 7.7 | 58.9 ± 9.4[ | 53.7 ± 4.9[ | 86.3 ± 2.8 | 84.5 ± 4.5 | 47.5 ± 2.8[ | 52.2 ± 4.7[ |
| ES volume (µL) | 57.5 ± 3.4 | 59.3 ± 6.1 | 31.6 ± 6.2[ | 30.4 ± 3.9[ | 47.7 ± 2.8 | 48.8 ± 3.2 | 25.7 ± 1.7[ | 30.0 ± 4.4[ |
| ED mass (mg) | 53.7 ± 7.1 | 53.0 ± 1.5 | 38.3 ± 4.1[ | 39.3 ± 3.2[ | 54.1 ± 3.2 | 59.1 ± 3.2 | 37.8 ± 1.9[ | 40.3 ± 1.5[ |
| ES mass (mg) | 59.1 ± 4.5 | 57.7 ± 6.7 | 43.2 ± 3.8 | 42.8 ± 4.1 | 60.3 ± 4.0 | 63.4 ± 4.6 | 40.2 ± 2.1[ | 43.0 ± 2.2[ |
| EF (%) | 38.1 ± 1.9 | 35.5 ± 1.7 | 47.4 ± 3.8 | 44.0 ± 2.0 | 44.6 ± 2.5 | 42.3 ± 1.9 | 45.5 ± 2.6 | 42.4 ± 3.0 |
2 or 6 weeks of sham or PAB.
Data are expressed as means ± SEM. ED, end-diastole; ES, end-systole; LV, left ventricle; EF, ejection fraction.
P < 0.05 vs. sham group.
n.s.=5–10 animals per group.